Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT

Launched by JIANYANG WANG · Jun 23, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for people with a type of lung cancer called locally advanced non-small cell lung cancer (LA-NSCLC) who cannot tolerate the usual combined chemotherapy and radiotherapy treatment. Instead of the standard method, which some patients cannot handle, this study is testing whether adding a drug called Anlotinib during radiotherapy can help improve the chances of the cancer staying under control for longer. The goal is to see if this combination can increase the time patients live without the cancer getting worse over two years.

The trial is open to adults aged 18 and older with a specific type of lung cancer that has certain genetic features (no EGFR mutations or certain other mutations). Participants should have a good overall health status, have already received some chemotherapy or immunotherapy without the cancer progressing, and meet other safety criteria like no active bleeding or serious heart or lung problems. If you join the study, you will receive radiotherapy along with the drug Anlotinib, and doctors will closely monitor you for side effects and how well the treatment is working. This study is currently recruiting patients, and it hopes to include about 44 people to better understand if this treatment can offer a safer and more effective option for those who cannot undergo the usual combined therapy.

Gender

ALL

Eligibility criteria

• • Patients with histologically or cytologically confirmed negative EGFR (including EGFR exon 19 deletion or L858R mutations) or ALK/ROS1-mutated locally advanced unresectable NSCLC were screened.
• Inclusion Criteria:
• • 1. ≥18 years old with no restrictions on sex;
• • 2. Peripheral tumor, or central lung cancer with non-squamous tissue or a mixed tissue with less than 50% squamous carcinoma;
• • 3. Eastern cooperative oncology group (ECOG) score ≤2 was required;
• • 4. Received systemic chemotherapy or combined chemotherapy and immumitherapy for ≥ 4 weeks without progression;
• • 5. .No cavity inside the tumor, and located ≥ 1 cm of the main pulmonary artery trunk;
• • 6. No symptoms of hemoptysis;
• • 7. Adequate hepatic and renal functions with a negative urine protein;
• • 8. Expected survival of more than 6 months.
• Exclusion Criteria:
• • 1. currently receiving treatment for malignancies at other sites, except for curable non-melanoma skin cancer and cervical carcinoma in situ;
• • 2. previous malignancy within five years;
• • 3. thoracic radiotherapy history, hemoptysis, myocardial infarction or cerebrovascular accident within three months;
• • 4. uncontrolled or active pulmonary inflammation;
• • 5. participated in other clinical trials;
• • 6. Pregnant women.